-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, August 25.
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
The original research product was approved for import just this month.
Currently, there are no generic drugs on sale in China
.
According to data from Meinenet, since 2021, Qilu Pharmaceuticals has 19 products approved for the market, 17 of which are generic drugs
.
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
The original research product was approved for import just this month.
Currently, there are no generic drugs on sale in China
.
According to data from Meinenet, since 2021, Qilu Pharmaceuticals has 19 products approved for the market, 17 of which are generic drugs
.
Source: official website of the State Drug Administration
Apomilast (apmilast/apmilast) is a new oral, small molecule phosphodiesterase 4 (PDE-4) inhibitor developed by New Base (acquired by Amgen), which is dose-dependent Sexually inhibits the release of tumor necrosis factor (TNF)-α from human synovial cells
.
The product was approved by the FDA in 2014, and its global sales in 2020 will reach 2.
195 billion US dollars
.
.
The product was approved by the FDA in 2014, and its global sales in 2020 will reach 2.
195 billion US dollars
.
In addition to apremilast, the PDE-4 inhibitors currently on the market worldwide also include cliborrol, doxofylline, roflumilast, etc.
, and apremilast is mainly used for psoriatic arthritis, psoriasis, etc.
, Cliborrol is mainly used for atopic dermatitis, and doxofylline and roflumilast can be used for respiratory diseases such as chronic obstructive pulmonary disease
.
Among them, apreste, cliborrol, and doxofylline have all been approved for import
.
, and apremilast is mainly used for psoriatic arthritis, psoriasis, etc.
, Cliborrol is mainly used for atopic dermatitis, and doxofylline and roflumilast can be used for respiratory diseases such as chronic obstructive pulmonary disease
.
Among them, apreste, cliborrol, and doxofylline have all been approved for import
.
Production status of Apster tablets
Source: Mi Nei Net Consistency Evaluation Database
Amgen’s Apster tablets were approved for import in August 2021.
At present, 8 domestic companies have submitted applications for the product’s listing under the new classification.
Among them , CSPC Ouyi is the first to apply for production, but Qilu’s products are the first to enter the administrative examination and approval process.
At this stage, who will be the final winner of the first imitation? We will wait and see
.
At present, 8 domestic companies have submitted applications for the product’s listing under the new classification.
Among them , CSPC Ouyi is the first to apply for production, but Qilu’s products are the first to enter the administrative examination and approval process.
At this stage, who will be the final winner of the first imitation? We will wait and see
.
Qilu approved products since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, since 2021, Qilu Pharmaceutical has 19 products approved for marketing, including 2 new drugs (all oral membranes) and 17 new generic drugs (3 first imitations)
.
com, since 2021, Qilu Pharmaceutical has 19 products approved for marketing, including 2 new drugs (all oral membranes) and 17 new generic drugs (3 first imitations)
.
Sales of 3 first generic drugs in Chinese public medical institutions and physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei Net Database
The 3 first generic drugs are rasagiline mesylate, metformin vildagliptin tablets and trifluridine tepipyrimine tablets.
The original products have been approved for import.
Among them, metformin vildagliptin will be available in 2020.
China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban entity pharmacies have a combined sales scale of nearly 80 million yuan
.
The original products have been approved for import.
Among them, metformin vildagliptin will be available in 2020.
China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban entity pharmacies have a combined sales scale of nearly 80 million yuan
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
Medical Network News, August 25.
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
The original research product was approved for import just this month.
Currently, there are no generic drugs on sale in China
.
According to data from Meinenet, since 2021, Qilu Pharmaceuticals has 19 products approved for the market, 17 of which are generic drugs
.
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
The original research product was approved for import just this month.
Currently, there are no generic drugs on sale in China
.
According to data from Meinenet, since 2021, Qilu Pharmaceuticals has 19 products approved for the market, 17 of which are generic drugs
.
Source: official website of the State Drug Administration
Apomilast (apmilast/apmilast) is a new oral, small molecule phosphodiesterase 4 (PDE-4) inhibitor developed by New Base (acquired by Amgen), which is dose-dependent Sexually inhibits the release of tumor necrosis factor (TNF)-α from human synovial cells
.
The product was approved by the FDA in 2014, and its global sales in 2020 will reach 2.
195 billion US dollars
.
.
The product was approved by the FDA in 2014, and its global sales in 2020 will reach 2.
195 billion US dollars
.
In addition to apremilast, the PDE-4 inhibitors currently on the market worldwide also include cliborrol, doxofylline, roflumilast, etc.
, and apremilast is mainly used for psoriatic arthritis, psoriasis, etc.
, Cliborrol is mainly used for atopic dermatitis, and doxofylline and roflumilast can be used for respiratory diseases such as chronic obstructive pulmonary disease
.
Among them, apreste, cliborrol, and doxofylline have all been approved for import
.
, and apremilast is mainly used for psoriatic arthritis, psoriasis, etc.
, Cliborrol is mainly used for atopic dermatitis, and doxofylline and roflumilast can be used for respiratory diseases such as chronic obstructive pulmonary disease
.
Among them, apreste, cliborrol, and doxofylline have all been approved for import
.
Production status of Apster tablets
Source: Mi Nei Net Consistency Evaluation Database
Amgen’s Apster tablets were approved for import in August 2021.
At present, 8 domestic companies have submitted applications for the product’s listing under the new classification.
Among them , CSPC Ouyi is the first to apply for production, but Qilu’s products are the first to enter the administrative examination and approval process.
At this stage, who will be the final winner of the first imitation? We will wait and see
.
At present, 8 domestic companies have submitted applications for the product’s listing under the new classification.
Among them , CSPC Ouyi is the first to apply for production, but Qilu’s products are the first to enter the administrative examination and approval process.
At this stage, who will be the final winner of the first imitation? We will wait and see
.
Qilu approved products since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, since 2021, Qilu Pharmaceutical has 19 products approved for marketing, including 2 new drugs (all oral membranes) and 17 new generic drugs (3 first imitations)
.
com, since 2021, Qilu Pharmaceutical has 19 products approved for marketing, including 2 new drugs (all oral membranes) and 17 new generic drugs (3 first imitations)
.
Sales of 3 first generic drugs in Chinese public medical institutions and physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei Net Database
The 3 first generic drugs are rasagiline mesylate, metformin vildagliptin tablets and trifluridine tepipyrimine tablets.
The original products have been approved for import.
Among them, metformin vildagliptin will be available in 2020.
China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban entity pharmacies have a combined sales scale of nearly 80 million yuan
.
The original products have been approved for import.
Among them, metformin vildagliptin will be available in 2020.
China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban entity pharmacies have a combined sales scale of nearly 80 million yuan
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
Medical Network News, August 25.
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
The original research product was approved for import just this month.
Currently, there are no generic drugs on sale in China
.
According to data from Meinenet, since 2021, Qilu Pharmaceuticals has 19 products approved for the market, 17 of which are generic drugs
.
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
The original research product was approved for import just this month.
Currently, there are no generic drugs on sale in China
.
According to data from Meinenet, since 2021, Qilu Pharmaceuticals has 19 products approved for the market, 17 of which are generic drugs
.
Source: official website of the State Drug Administration
Apomilast (apmilast/apmilast) is a new oral, small molecule phosphodiesterase 4 (PDE-4) inhibitor developed by New Base (acquired by Amgen), which is dose-dependent Sexually inhibits the release of tumor necrosis factor (TNF)-α from human synovial cells
.
The product was approved by the FDA in 2014, and its global sales in 2020 will reach 2.
195 billion US dollars
.
Tumor tumor tumor.
The product was approved by the FDA in 2014, and its global sales in 2020 will reach 2.
195 billion US dollars
.
In addition to apremilast, the PDE-4 inhibitors currently on the market worldwide also include cliborrol, doxofylline, roflumilast, etc.
, and apremilast is mainly used for psoriatic arthritis, psoriasis, etc.
, Cliborrol is mainly used for atopic dermatitis, and doxofylline and roflumilast can be used for respiratory diseases such as chronic obstructive pulmonary disease
.
Among them, apreste, cliborrol, and doxofylline have all been approved for import
.
Disease disease disease, and apremilast is mainly used for psoriatic arthritis, psoriasis, etc.
, Cliborrol is mainly used for atopic dermatitis, and doxofylline and roflumilast can be used for respiratory diseases such as chronic obstructive pulmonary disease
.
Among them, apreste, cliborrol, and doxofylline have all been approved for import
.
Production status of Apster tablets
Source: Mi Nei Net Consistency Evaluation Database
Amgen’s Apster tablets were approved for import in August 2021.
At present, 8 domestic companies have submitted applications for the product’s listing under the new classification.
Among them , CSPC Ouyi is the first to apply for production, but Qilu’s products are the first to enter the administrative examination and approval process.
At this stage, who will be the final winner of the first imitation? We will wait and see
.
Enterprise business enterpriseAt present, 8 domestic companies have submitted applications for the product’s listing under the new classification.
Among them , CSPC Ouyi is the first to apply for production, but Qilu’s products are the first to enter the administrative examination and approval process.
At this stage, who will be the final winner of the first imitation? We will wait and see
.
Qilu approved products since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, since 2021, Qilu Pharmaceutical has 19 products approved for marketing, including 2 new drugs (all oral membranes) and 17 new generic drugs (3 first imitations)
.
com, since 2021, Qilu Pharmaceutical has 19 products approved for marketing, including 2 new drugs (all oral membranes) and 17 new generic drugs (3 first imitations)
.
Sales of 3 first generic drugs in Chinese public medical institutions and physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei Net Database
The 3 first generic drugs are rasagiline mesylate, metformin vildagliptin tablets and trifluridine tepipyrimine tablets.
The original products have been approved for import.
Among them, metformin vildagliptin will be available in 2020.
China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban entity pharmacies have a combined sales scale of nearly 80 million yuan
.
Hospital hospital hospital pharmacy pharmacy pharmacyThe original products have been approved for import.
Among them, metformin vildagliptin will be available in 2020.
China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban entity pharmacies have a combined sales scale of nearly 80 million yuan
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
Source: Mi Nei. com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
